Literature DB >> 11460259

Septo-optic dysplasia as a manifestation of valproic acid embryopathy.

C L McMahon1, S R Braddock.   

Abstract

BACKGROUND: The use of valproic acid during pregnancy has been associated with adverse fetal outcomes, including major and minor congenital malformations, intrauterine growth retardation (IUGR), hyperbilirubinemia, hepatotoxicity, transient hyperglycemia, and fetal and neonatal distress. In addition, intrauterine exposure to valproic acid has been associated with an increased risk of central nervous system abnormalities, primarily neural tube defects. Optic nerve hypoplasia has been reported in association with other prenatal anticonvulsant exposures, but the occurrence of septo-optic dysplasia as a manifestation of valproic acid embryopathy has not been reported previously.
RESULTS: We report on a woman who received Depakote (valproic acid) throughout her pregnancy for the treatment of a seizure disorder. The patient presented with features typical of valproic acid embryopathy, including bitemporal narrowing, hypertelorism, short palpebral fissures, epicanthal folds, microphthalmia, a flat broad nasal bridge, small mouth, hypoplastic nails, mild clinodactyly, and camptodactyly. MRI showed hypoplasia of the optic chiasm and absence of the septum pellucidum.
CONCLUSIONS: We report the first case of septo-optic dysplasia associated with maternal exposure to valproic acid throughout pregnancy. This case expands the clinical phenotype of valproate embryopathy. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11460259     DOI: 10.1002/tera.1049

Source DB:  PubMed          Journal:  Teratology        ISSN: 0040-3709


  7 in total

Review 1.  Medical genetics: 1. Clinical teratology in the age of genomics.

Authors:  Janine E Polifka; J M Friedman
Journal:  CMAJ       Date:  2002-08-06       Impact factor: 8.262

Review 2.  Prenatal determinants of optic nerve hypoplasia: review of suggested correlates and future focus.

Authors:  Pamela Garcia-Filion; Mark Borchert
Journal:  Surv Ophthalmol       Date:  2013 Nov-Dec       Impact factor: 6.048

3.  Optic nerve hypoplasia syndrome: a review of the epidemiology and clinical associations.

Authors:  Pamela Garcia-Filion; Mark Borchert
Journal:  Curr Treat Options Neurol       Date:  2013-02       Impact factor: 3.598

4.  Optic nerve hypoplasia in North America: a re-appraisal of perinatal risk factors.

Authors:  Pamela Garcia-Filion; Cassandra Fink; Mitchell E Geffner; Mark Borchert
Journal:  Acta Ophthalmol       Date:  2008-12-24       Impact factor: 3.761

Review 5.  The syndrome of optic nerve hypoplasia.

Authors:  Mark Borchert; Pamela Garcia-Filion
Journal:  Curr Neurol Neurosci Rep       Date:  2008-09       Impact factor: 5.081

Review 6.  Impact of early life exposure to antiepileptic drugs on neurobehavioral outcomes based on laboratory animal and clinical research.

Authors:  Kevin G Bath; Helen E Scharfman
Journal:  Epilepsy Behav       Date:  2013-01-08       Impact factor: 2.937

7.  Identification of brain malformations: neuropathological approach.

Authors:  Férechté Encha-Razavi
Journal:  Childs Nerv Syst       Date:  2003-06-11       Impact factor: 1.475

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.